Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL9146358 | 0.98 | F12 (0.53) | F12L3MBTL1HTTGAAKDM4E | |
| SCHEMBL61339 | 0.96 | F12 (0.59) | F12L3MBTL1HTTGAAKDM4E | |
| Formaldehyde SCHEMBL28698810 | 0.94 | F12 (0.57) | F12L3MBTL1HTTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL1719468 | 0.94 | F12 (0.57) | F12L3MBTL1HTTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL28900590 | 0.92 | F12 (0.55) | F12L3MBTL1HTTGAAKDM4E | |
| SCHEMBL10491687 | 0.84 | KMT2A (0.50) | F12L3MBTL1HTTGAAKDM4E | |
| Glutaral SCHEMBL7745284 | 0.81 | F12 (0.49) | F12L3MBTL1HTTKDM4EPKM | |
| SCHEMBL29051410 | 0.81 | F12 (0.49) | F12 | |
| Hydrazine SCHEMBL145701 | 0.80 | MAPT (0.49) | F12L3MBTL1MAPTKMT2ANPC1 | |
| Iminostilbene SCHEMBL8502208 | 0.79 | GAA (0.47) | F12L3MBTL1HTTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160077013-A1 | Laminated Detector for Detection and Quantitative Determination of Formaldehyde | Appealing Products, Inc. | 2016-03-17 | — | — | US | claimed |
| US-8815532-B2 | Color-producing diagnostic systems, reagents and methods | DIAGNOSTIC INNOVATIONS, LLC (US) | 2014-08-26 | — | — | US | claimed |
| US-RE39352-E1 | Creatine amidinohydrolase, production thereof and use thereof | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2006-10-17 | — | — | US | claimed |
| US-RE38687-E1 | Creatine amidinohydrolase, production thereof and use thereof | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2005-01-11 | — | — | US | claimed |
| US-6080553-A | ENZYME HAVING A VERY LOW MICHAELIS CONSTANT (KM) VALUE FOR CREATINE; FOR USE AS GENERAL REAGENT IN CLINICAL/DIAGNOSTIC TESTS | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2000-06-27 | — | — | US | claimed |
| EP-0479394-B1 | Meter for measuring the concentration of an analyte in whole blood and kit comprising the same | LIFESCAN INC (US) | 1998-12-16 | — | — | EP | claimed |
| EP-0790303-A1 | Novel creatine amidinohydrolase, production thereof and use thereof | Toyo Boseki Kabushiki Kaisha (JP) | 1997-08-20 | — | — | EP | claimed |
| CN-114848841-B | Preparation of bionic MOF nanocapsules for rapidly degrading ethanol and application of bionic MOF nanocapsules in alcoholism treatment | 山东大学 | 2024-05-28 | — | — | CN | disclosed |
| EP-3492600-B1 | METHOD FOR MEASURING GLYCATED HEMOGLOBIN | HITACHI CHEMICAL DIAGNOSTICS SYSTEMS CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-20230358767-A1 | METHOD FOR REDUCING MEASUREMENT ERROR | SEKISUI MEDICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| EP-4212627-A1 | METHOD FOR REDUCING MEASUREMENT ERROR | Sekisui Medical Co., Ltd. (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-11672846-B2 | Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm | THE HOSPITAL FOR SICK CHILDREN (CA) | 2023-06-13 | — | — | US | disclosed |
| CN-116075594-A | Method for reducing measurement error | 积水医疗株式会社 | 2023-05-05 | — | — | CN | disclosed |
| EP-0465577-B1 | CATALYZED REPORTER DEPOSITION | DU PONT (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5183742-A | Useful for early detection, diagnosis and control of diseases such as diabetes, gastropathy, naphropathy and hepatic insufficiency | DAI NIPPON INSATSU KABUSHIKI KAISHA (JP) | 1993-02-02 | — | — | US | disclosed |
| US-5182203-A | Amplification of detector signals in immunoassays | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0465577-A1 | CATALYZED REPORTER DEPOSITION. | DU PONT (US) | 1992-01-15 | — | — | EP | disclosed |
| WO-1990011523-A2 | CATALYZED REPORTER DEPOSITION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-04 | — | — | WO | disclosed |
| US-4778757-A | ADDING FIRST REAGENT OF OXIDASE, PEROXIDASE AND PHENOLIC CHROMOGEN FOLLOWED BY ADDING COUPLER; ACCURATE COLORIMETRY | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4071405-A | BETA- OR GAMMA-AMINO ACIDS, METHIONINASE | AJINOMOTO CO., INC. (JA) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230358767-A1 | METHOD FOR REDUCING MEASUREMENT ERROR | CAT, MPO, UCHL1 | F12 406/4885L3MBTL1 1460/4885HTT 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.